Alliance acquires brands from Reckitt Benckiser
This article was originally published in Scrip
Executive Summary
Alliance Pharma is to buy the worldwide rights to the nausea treatment Buccastem (prochlorperazine) and the antifungal Timodine (nystatin plus hydrocortisone 0.5%) from Reckitt Benckiser for £7.5 million.